Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of LDP in urologic and male genital tumors
CTR20201949Phase 2Active
- Sponsor
- Dragon Sail Pharmaceutical
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of lesabelimab in bladder cancer, non-clear cell renal cell carcinoma (nccRCC), penile cancer, sponsored by Dragon Sail Pharmaceutical. Started Jan 2021; status: active.
02
Drugs
lesabelimab
03
Conditions
bladder cancernon-clear cell renal cell carcinoma (nccRCC)penile cancer
Beyond the preview
Go deeper on CTR20201949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201949.